Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients

Journal of Clinical Psychiatry

Volumn 75, Issue 9, 2014, Pages e899-e905

  Ebdrup, Bjørn H ^b   Knop, Filip K ^c,d   Madsen, Anna ^a   Mortensen, Henrik B ^c   Søgaard, Birgitte ^e   Holst, Jens J ^d   Szecsi, Pal B ^c   Lublin, Henrik ^b  

^a Mental Health Center Glostrup   (Denmark)

^b Psychiatric Centre Glostrup   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NNF Center for Basic Metabolism Research   (Denmark)

^e H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOMETABOLIC HORMONE; GLUCOSE; HEMOGLOBIN A1C; HORMONE; INCRETIN; INSULIN; INTERLEUKIN 6; LEPTIN; NEUROLEPTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; GASTROINTESTINAL HORMONE;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; ICD-10; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; ADOLESCENT; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHEMICALLY INDUCED; DISORDERS OF CARBOHYDRATE METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; YOUNG ADULT;

ADIPONECTIN; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; C-PEPTIDE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON; GLUCOSE METABOLISM DISORDERS; HUMANS; INSULIN; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84922069378     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08820     Document Type: Article

References (60)

1. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071. doi:10.1016/S0140-6736(12)60239-6 PubMed
2. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298(15):1794-1796. doi:10.101/jama.298.15.1794 PubMed
3. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233. doi:10.1016/j.schres.2010.07.012 PubMed
4. Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067-1075. PubMed
5. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;CD006633. PubMed
6. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654. doi:10.102/14651858.cd0654.pub2 PubMed
7. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366(9491):1059-1062. doi:10.1016/S0140-6736(05)67402-8 PubMed
8. Alberti KG, Eckel RH, Grundy SM, et al; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. doi:10.161/CIRCULATIONAHA.109.19264 PubMed
9. De HertM, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114-126.
10. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. 2011;343(1):d5422. doi:10.136/bmj.d542 PubMed
11. Nordentoft M, Wahlbeck K, Hallgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS ONE. 2013;8(1):e55176. doi:10.1371/journal.pone.05176 PubMed
12. Orci L, Unger RH. Functional subdivision of islets of Langerhans and possible role of D cells. Lancet. 1975;306(7947):1243-1244. doi:10.1016/S0140-6736(75)92078-4 PubMed
13. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagonlike peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326(20):1316-1322. doi:10.1056/NEJM1920514326203 PubMed
14. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837. doi:10.1016/j.cmet.2013.04.08 PubMed
15. van der Lely AJ, Tschop M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25(3):426-457. doi:10.1210/er.202-029 PubMed
16. DeBoer MD. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions. Nutrition. 2013;29(2):379-386. doi:10.1016/j.nut.2012.07.03 PubMed
17. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98(10):E1610-E1619. doi:10.1210/jc.2013-2038 PubMed
18. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J. 1982;207(3):381-388. PubMed
19. Krarup T, Madsbad S, Moody AJ, et al. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab. 1983;56(6):1306-1312. doi:10.1210/jcem-56-6-1306 PubMed
20. Orskov C, Rabenhoj L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535-539. doi:10.237/diab.43.4.535 PubMed
21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. doi:10.107/BF028083 PubMed
22. Tura A, Pacini G, Kautzky-Willer A, et al. Basal and dynamic proinsulininsulin relationship to assess beta-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab. 2003;285(1):E155-E162. PubMed
23. Faerch K, Vaag A, Holst JJ, et al. Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care. 2009;32(3):439-444. doi:10.237/dc08-195 PubMed
24. Knop FK, Aaboe K, Vilsboll T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab. 2012;14(6):500-510. doi:10.1/j.1463-1326.201.01549.x PubMed
25. Vik-Mo AO, Birkenaes AB, Ferno J, et al. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol. 2008;11(5):679-684. doi:10.1017/S14614570808468 PubMed
26. Vidarsdottir S, Vlug P, Roelfsema F, et al. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry. 2010;71(9):1205-1211. doi:10.408/JCP.08m04654yel PubMed
27. Ferno J, Skrede S, Vik-Mo AO, et al. Lipogenic effects of psychotropic drugs: focus on the SREBP system. Front Biosci (Landmark Ed). 2011;16(1):49-60. doi:10.2741/3675 PubMed
28. Mann S, Chintoh A, Giacca A, et al. Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition. Pharmacol Biochem Behav. 2013;103(4):717-722. doi:10.1016/j.pb.2012.12.02 PubMed
29. Grad E, Danenberg HD. C-reactive protein and atherothrombosis: cause or effect? Blood Rev. 2013;27(1):23-29. doi:10.1016/j.blre.2012.12.01 PubMed
30. Chen SL, Lee SY, Chang YH, et al. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharmacol. 2012;7(3):656-664. doi:10.107/s1481-012-9382-z PubMed
31. Carrizo E, Fernandez V, Quintero J, et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res. 2008;103(1-3):83-93. doi:10.1016/j.schres.208.03.04 PubMed
32. Loffler S, Klimke A, Kronenwett R, et al. Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol. 2010;30(5):591-595. doi:10.1097/JCP.0b013e3181eb7f7 PubMed
33. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006;186(4):572-578. doi:10.107/s0213-06-0384-5 PubMed
34. Wu MK, Huang CY, Liou YJ, et al. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int J Obes (Lond). 2008;32(3):436-442. doi:10.1038/sj.ijo.0803750 PubMed
35. Birkenaes AB, Birkeland KI, Friis S, et al. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions. J Clin Psychopharmacol. 2009;29(2):109-116. doi:10.1097/JCP.0b013e31819b95fc PubMed
36. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006;67(5):789-797. doi:10.408/JCP.v67n0513 PubMed
37. Newcomer JW, Ratner RE, Eriksson JW, et al. A 24-week, multicenter, openlabel, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry. 2009;70(4):487-499. doi:10.408/JCP.08m04132 PubMed
38. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotictreated patients. Neuropsychopharmacology. 2007;32(12):2561-2569. doi:10.1038/sj.np.1301392 PubMed
39. Vidarsdottir S, Roelfsema F, Streefland T, et al. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur J Endocrinol. 2010;162(1):75-83. doi:10.1530/EJE-09-043 PubMed
40. Smith GC, Vickers MH, Shepherd PR. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem. 2011;117(4):241-249. doi:10.3109/1381345.201.57681 PubMed
41. Teff KL, Rickels MR, Grudziak J, et al. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62(9):3232-3240. doi:10.237/db13-0430 PubMed
42. Faerch K, Vaag A, Holst JJ, et al. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia. 2008;51(5):853-861. doi:10.107/s0125-08-0951-x PubMed
43. Sondhi S, Castellano JM, Chong VZ, et al. cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects. Pharmacogenomics J. 2006;6(2):131-140. doi:10.1038/sj.tpj.650346 PubMed
44. Christensen M, Vedtofte L, Holst JJ, et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103-3109. doi:10.237/db1-0979 PubMed
45. Ugleholdt R, Pedersen J, Bassi MR, et al. Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain. J Biol Chem. 2011;286(52):44632-44645. doi:10.1074/jbc.M1.3179 PubMed
46. Kamoi K, Shinozaki Y, Furukawa K, et al. Potential correlation between plasma total GIP levels and body mass index in Japanese patients with types 1 or 2 diabetes mellitus. Endocr J. 2012;59(4):353-363. doi:10.1507/endocrj.EJ1-0245 PubMed
47. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. doi:10.152/physrev.034.206 PubMed
48. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344(2):d7771. doi:10.136/bmj.d71 PubMed
49. Ebdrup BH, Knop FK, Ishoy PL, et al. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med. 2012;10(1):92. doi:10.186/1741-7015-10-92 PubMed
50. Ishoy PL, Knop FK, Vilsboll T, et al. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry. 2013;170(6):681-682. doi:10.176/api.ajp.2013.1210134 PubMed
51. Ishoy PL, Knop FK, Broberg BV, et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist - protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open. 2014;4(1):e004158. doi:10.136/bmjopen-2013-04158 PubMed
52. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56(5):965-972. doi:10.107/s0125-013-2841-0 PubMed
53. Sentissi O, Epelbaum J, Olie JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull. 2008;34(6):1189-1199. doi:10.1093/schbul/sbm141 PubMed
54. Esen-Danaci A, Sarandol A, Taneli F, et al. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1434-1438. doi:10.1016/j.pnpbp.208.03.015 PubMed
55. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68(12):1834-1839. doi:10.408/JCP.v68n1202 PubMed
56. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184(1):58-62. doi:10.192/bjp.184.1.58 PubMed
57. van Welie H, Derks EM, Verweij KH, et al. The prevalence of diabetes mellitus is increased in relatives of patients with a non-affective psychotic disorder. Schizophr Res. 2013;143(2-3):354-357. doi:10.1016/j.schres.2012.1.01 PubMed
58. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007;27(4):374-379. doi:10.1097/JCP.0b013e3180cac8db PubMed
59. Patel JK, Buckley PF, Woolson S, et al; CAFE Investigators. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111(1-3):9-16. doi:10.1016/j.schres.209.03.025 PubMed
60. Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125-147. doi:10.1017/S03291710105X PubMed